Summary of 2020
The year 2020 was the year of COVID-19. It was also Inven2’s tenth anniversary. However, it was also a year in which much value was created from the research carried out at the University of Oslo, Oslo University Hospital and the other health trusts in the South-Eastern Norway Regional Health Authority.
Gain insight into success stories, strategic activities and key figures.
Latest news
More news
Latest news
Here you can read the latest news regarding Inven2s portfolio businesses, innovation projects and clinical studies. Every month we write longer articles where we interview current researchers and clinicians.
A unique biological super-taxi has been developed
Most protein-based therapeutics must be injected to be effective. That is both stressful for the patient and costly for the healthcare system....
First in the world with unique immunotherapy
Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on a new form of cancer...
SJJ Solutions signs industry development agreement with Inven2
The Dutch medical device company SJJ Solutions, the Department of Ophthalmology at Oslo University Hospital and the Laboratory of Adaptive Immunity...
Events
More events
Events
There are no upcoming events at this time.
Innovation
Inven2’s core business is innovation. We contribute in the process of commersialising good ideas from talented researchers, turning them into products and services that make a difference.
Clinical studies
Inven2 work closely with hospitals and companies to make sure clinical studies are completed quick and efficient, to the best for Norwegian patients.
Key figures 2010 – 2020
# Ideas evaulated (DOFI)
# Companies established
# Licence agreements
# New patent applications
MNOK transferred back to research, innovation and inventors
# Clinical Trials managed
Portfolio businesses
More businesses
Portfolio businesses
Inven2 has a portfolio comprising 53 companies. We have established them either on our own or alongside investors to commercialise research results from innovative researchers. The point of departure for the companies are research results from innovative researchers. The portfolio value in October 2020 is NOK 23 billion, but this will vary with the value of the individual company and how long we are shareholders in the most valuable companies.
Products on the market
More products
Products on the market
Inven2 has contributed to many products and services that have served society well through licensing to industry or business start-ups within a range of technology fields. What follows is a selection of them.
EPISHUTTLE – Transport isolator
Photo: EpiGuard
QUEST 5 HMC DNA ELISA KIT Epigenetic kit
Photo: Zymo Research
PROBNP – Heart disease test
Photo: Roche
